"Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware delivering state-of-the-art, comprehensive patient care for over 40 years. Our retina specialists are world-renowned and board-certified physicians with over 400 years of combined expertise. They are recognized as leaders in vitreoretinal diseases by ophthalmology and medical societies. We are dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of restoring and maintaining sight to improve the quality of life for our patients. See a Wills Eye Doctor near Philadelphia today."

During the past decade, Mid Atlantic Retina conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Atlantic Retina" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 2 trials, followed by "Aerpio Therapeutics" with 1 trials sponsored, "Bayer" with 1 trials sponsored, "Curacle Co., Ltd." with 1 trials sponsored and "Wills Eye" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Atlantic Retina" #1 collaborator was "Laboratorios Thea, France" with 1 trials as a collaborator, "Mid Atlantic Retina" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Mid Atlantic Retina" are "Central Serous Chorioretinopathy" (1 trials), "Diabetic Macular Edema" (1 trials), "Geographic Atrophy" (1 trials), "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials) and "Neovascular Age-Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Mid Atlantic Retina" in a lesser frequency.

Most popular intervention types in "Mid Atlantic Retina" are "Drug" (6 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "25mg Eplerenone" (1 trials), "AKB-9778" (1 trials), "APL-2" (1 trials) and "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mid Atlantic Retina" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Mid Atlantic Retina". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mid Atlantic Retina, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mid Atlantic Retina, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".